Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer

BMC Research Notes

Thomas Brüning³  Jens Kollmeier²  Karl-Heinz Jöckel¹  Beate Pesch³  Oleksandr Bryk³  Swaantje Casjens³  Georg Johnen³  Daniel Gilbert Weber³ 

[1] Institute of Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, Germany;HELIOS Clinic Emil von Behring, Respiratory Diseases Clinic Heckeshorn, Walterhöferstrasse 11, 14165 Berlin, Germany;Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr-Universität Bochum (IPA), Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany

关键词: Specificity;    Sensitivity;    Minimally-invasive;    MALAT1;    lncRNA;    Biomarkers;    NSCLC;    Cancer;    Lung;   

Others  :  1140540
DOI  :  10.1186/1756-0500-6-518

 received in 2013-08-22, accepted in 2013-11-29,  发布年份 2013

【 摘 要 】

Background

The long noncoding RNA MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) is described as a potential biomarker for NSCLC (non-small cell lung cancer). Diagnostic biomarkers need to be detectable in easily accessible body fluids, should be characterized by high specificity, sufficient sensitivity, and robustness against influencing factors. The aim of this study was to evaluate the performance of MALAT1 as a blood based biomarker for NSCLC.

Results

MALAT1 was shown to be detectable in the cellular fraction of peripheral human blood, showing different expression levels between cancer patients and cancer-free controls. For the discrimination of NSCLC patients from cancer-free controls a sensitivity of 56% was calculated conditional on a high specificity of 96%. No impact of tumor stage, age, gender, and smoking status on MALAT1 levels could be observed, but results based on small numbers.

Conclusions

The results of this study indicate that MALAT1 complies with key characteristics of diagnostic biomarkers, i.e., minimal invasiveness, high specificity, and robustness. Due to its relatively low sensitivity MALAT1 might not be feasible as a single biomarker for the diagnosis of NSCLC in the cellular fraction of blood. Alternatively, MALAT1 might be applicable as a complementary biomarker within a panel in order to improve the entire diagnostic performance.

【 授权许可】

   
2013 Weber et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [2]Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L: International Association for the Study of Lung Cancer International Staging C, Participating I: the IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007, 2:706-714.
• [3]Ambros V: The functions of animal microRNAs. Nature 2004, 431:350-355.
• [4]Kent OA, Mendell JT: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006, 25:6188-6196.
• [5]Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ: miR-1254 and miR-574-5p: Serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol 2011, 6:482-488.
• [6]Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, Wang MX: Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 2011, 4:575-586.
• [7]Bianchi F, Nicassio F, Marzi M, Belloni E, Dall'olio V, Bernard L, Pelosi G, Maisonneuve P, Veronesi G, Di Fiore PP: A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 2011, 3:495-503.
• [8]Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabro E, Croce CM, Pastorino U, Sozzi G: MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA 2011, 108:3713-3718.
• [9]Pass HI, Beer DG, Joseph S, Massion P: Biomarkers and molecular testing for early detection, diagnosis, and therapeutic prediction of lung cancer. Thorac Surg Clin 2013, 23:211-224.
• [10]Reis EM, Verjovski-Almeida S: Perspectives of long non-coding RNAs in cancer diagnostics. Front Genet 2012, 3:32.
• [11]Tano K, Akimitsu N: Long non-coding RNAs in cancer progression. Front Genet 2012, 3:219.
• [12]Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, Zatloukal K: Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007, 132:330-342.
• [13]Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, Masse B, Piche L, Chypre C: uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004, 64:311-315. discussion 315–316
• [14]Schmidt LH, Spieker T, Koschmieder S, Schäffers S, Humberg J, Jungen D, Bulk E, Hascher A, Wittmer D, Marra A, et al.: The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol 2011, 6:1984-1992.
• [15]Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, et al.: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003, 22:8031-8041.
• [16]Lin R, Maeda S, Liu C, Karin M, Edgington TS: A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 2007, 26:851-858.
• [17]Sobin LH, Gospodarowicz MK, Wittekind C: International Union against Cancer.: TNM classification of malignant tumours. 7th edn. Chichester, West Sussex, UK. Wiley-Blackwell: Hoboken, NJ; 2010.
• [18]Schmermund A, Möhlenkamp S, Stang A, Grönemeyer D, Seibel R, Hirche H, Mann K, Siffert W, Lauterbach K, Siegrist J, et al.: Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL study. Risk factors, evaluation of coronary calcium and lifestyle. Am Heart J 2002, 144:212-218.
• [19]Guthrie JL, Seah C, Brown S, Tang P, Jamieson F, Drews SJ: Use of Bordetella pertussis BP3385 to establish a cutoff value for an IS481-targeted real-time PCR assay. J Clin Microbiol 2008, 46:3798-3799.
• [20]Ning B, Dial S, Sun Y, Wang J, Yang J, Guo L: Systematic and simultaneous gene profiling of 84 drug-metabolizing genes in primary human hepatocytes. J Biomol Screen 2008, 13:194-201.
• [21]Xie F, Xiao P, Chen D, Xu L, Zhang B: miRDeepFinder: a miRNA analysis tool for deep sequencing of plant small RNAs. Plant Mol Biol 2012, 80:75-84.
• [22]Vandesompele J, De Preter K, Pattyn F, Poppe B, van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3:RESEARCH0034.1-0034.11.
• [23]Andersen CL, Jensen JL, Orntoft TF: Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004, 64:5245-5250.
• [24]Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP: Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper–Excel-based tool using pair-wise correlations. Biotechnol Lett 2004, 26:509-515.
• [25]Silver N, Best S, Jiang J, Thein SL: Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR. BMC Mol Biol 2006, 7:33. BioMed Central Full Text
• [26]Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al.: The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 2013, 73:1180-1189.
• [27]Becker C, Hammerle-Fickinger A, Riedmaier I, Pfaffl MW: mRNA and microRNA quality control for RT-qPCR analysis. Methods 2010, 50:237-243.
• [28]Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N: Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol 2008, 9:76. BioMed Central Full Text
• [29]Schmittgen TD, Zakrajsek BA: Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. J Biochem Biophys Methods 2000, 46:69-81.
• [30]Gresner P, Gromadzinska J, Wasowicz W: Reference genes for gene expression studies on non-small cell lung cancer. Acta Biochim Pol 2009, 56:307-316.
• [31]Falkenberg VR, Whistler T, Murray JR, Unger ER, Rajeevan MS: Identification of Phosphoglycerate Kinase 1 (PGK1) as a reference gene for quantitative gene expression measurements in human blood RNA. BMC Res Notes 2011, 4:324. BioMed Central Full Text
• [32]Ulivi P, Mercatali L, Casoni GL, Scarpi E, Bucchi L, Silvestrini R, Sanna S, Monteverde M, Amadori D, Poletti V, Zoli W: Multiple marker detection in peripheral blood for NSCLC diagnosis. PLoS One 2013, 8:e57401.
• [33]Weber DG, Johnen G, Bryk O, Jöckel KH, Brüning T: Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant Mesothelioma - a pilot study. PLoS One 2012, 7:e30221.
• [34]Häusler SF, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S, Krockenberger M, Engel JB, Hönig A, Scheffler M, et al.: Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer 2010, 103:693-700.
• [35]Zhang PJ, Wei R, Wen XY, Ping L, Wang CB, Dong ZN, Deng XX, Bo W, Bin C, Tian YP: Genes expression profiling of peripheral blood cells of patients with hepatocellular carcinoma. Cell Biol Int 2012, 36:803-809.
• [36]Eissmann M, Gutschner T, Hämmerle M, Günther S, Caudron-Herger M, Gross M, Schirmacher P, Rippe K, Braun T, Zörnig M, Diederichs S: Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development. RNA Biol 2012, 9:1076-1087.
• [37]Arita T, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Shoda K, Kawaguchi T, Hirajima S, Nagata H, Kubota T, et al.: Circulating long non-coding RNAs in plasma of patients with gastric cancer. Anticancer Res 2013, 33:3185-3193.
• [38]Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, Wei M, Xu C, Wu C, Zhang Z, et al.: Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer 2013, 49:2949-2959.
• [39]Kogure T, Yan IK, Lin WL, Patel T: Extracellular vesicle-mediated transfer of a novel long noncoding RNA TUC339: a mechanism of intercellular signaling in human hepatocellular cancer. Genes & Cancer 2013, 4:261-272.
• [40]Tani H, Nakamura Y, Ijiri K, Akimitsu N: Stability of MALAT-1, a nuclear long non-coding RNA in mammalian cells, varies in various cancer cells. Drug Discoveries & Therapeutics 2010, 4:235-239.
• [41]Weber DG, Casjens S, Rozynek P, Lehnert M, Zilch-Schöneweis S, Bryk O, Taeger D, Gomolka M, Kreuzer M, Otten H, et al.: Assessment of mRNA and microRNA stabilization in peripheral human blood for multicenter studies and biobanks. Biomark Insights 2010, 5:95-102.
• [42]Matheson LA, Duong TT, Rosenberg AM, Yeung RS: Assessment of sample collection and storage methods for multicenter immunologic research in children. J Immunol Methods 2008, 339:82-89.
• [43]Kruhoffer M, Dyrskjot L, Voss T, Lindberg RL, Wyrich R, Thykjaer T, Orntoft TF: Isolation of microarray-grade total RNA, microRNA, and DNA from a single PAXgene blood RNA tube. J Mol Diagn 2007, 9:452-458.
• [44]Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC Jr, Moore LE, et al.: A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res 2011, 4:375-383.
• [45]Mai PL, Wentzensen N, Greene MH: Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer Prev Res 2011, 4:303-306.
• [46]Gutschner T, Hämmerle M, Diederichs S: MALAT1 - a paradigm for long noncoding RNA function in cancer. J Mol Med 2013, 91:791-801.